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Abstract
Background Bone complications, also known as skeletal-
related events (SREs), are common in patients with bone
metastases secondary to advanced cancers.
Objective To provide a detailed estimate of the health
resource utilization (HRU) burden associated with SREs
across eight European countries.
Methods Eligible patients from centers in Austria, the
Czech Republic, Finland, Greece, Poland, Portugal, Swe-
den, and Switzerland with bone metastases or lesions sec-
ondary to breast cancer, prostate, or lung cancer or multiple
myeloma who had experienced at least one SRE (defined as
radiation to bone, long-bone pathologic fracture, other
bone pathologic fracture, surgery to bone or spinal cord
compression) were entered into this study. HRU data were
extracted retrospectively from the patients’ charts from
3.5 months before the index SRE until 3 months after the
index SRE (defined as an SRE preceded by an SRE-free
period of at least 6.5 months).
Results Overall, the mean number of inpatient stays per
SRE increased from baseline by approximately 0.5–1.5
stays, with increases in the total duration of inpatient stays
of approximately 6–37 days per event. All SREs were
associated with substantial increases from baseline in the
frequency of procedures and the number of outpatient and
day-care visits.
Conclusions SREs are associated with substantial HRU
owing to considerable increases in the number and duration
of inpatient stays, and in the number of procedures, out-
patient visits, and day-care visits. These data collectively
provide a valuable summary of the real-world SRE burden
on European healthcare systems.
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Introduction
The progression of cancer to the skeleton is a common
occurrence in patients with advanced disease; at post-
mortem examination, 65–90 % of patients with breast or
prostate cancer and approximately 35 % of individuals
with lung cancer have bone metastases [1, 2] and almost all
patients with multiple myeloma develop bone lesions [3].
Metastatic bone disease is the cause of considerable mor-
bidity [2], with affected patients at high risk of experi-
encing bone complications, also referred to as skeletal-
related events (SREs), including radiation to bone, patho-
logic fracture, surgery to bone, and spinal cord compres-
sion [4]. Unless patients are treated with a bone-targeting
agent (BTA), SREs may occur as frequently as every
3–6 months [2]. As mobility and functional independence
diminish with subsequent SREs, overall health-related
quality of life also declines [4]. Furthermore, patients with
metastatic bone disease and an SRE have a poorer prog-
nosis and increased risk of death compared with patients
who are SRE naı¨ve [5–7].
Following an SRE, patient care and treatment can be
costly, as well as placing a considerable and complex
demand on healthcare resources [8–10]. A retrospective
analysis from the Netherlands estimated that the mean per
patient cost to treat SREs in individuals with prostate cancer
and bone metastases was €6973 (range, €1187–€40,948)
[11]. Despite the differences in the healthcare systems in the
Netherlands and the UK, similar values have been reported
for patients in the UK with breast cancer and bone metas-
tases, with an estimated mean lifetime SRE-associated cost
of £11,314–£19,121 (€14,029–€23,710; 1 GBP = 1.24
EUR) [12]. Notably, total medical care costs are substan-
tially higher for patients who have bone metastases and one
or more SREs than for those with bone metastases and no
SREs (estimated US$48,173 [€37,093; 1 US$ = 0.77 EUR]
more per patient per 60 months in the USA) [13].
Although some studies have attempted to estimate SRE-
associated costs, there are a limited number of analyses that
review specific health resource utilization (HRU) associ-
ated with SREs, particularly at a country level within
Europe. An analysis from Spain found that patients
(N = 28,162) with bone metastases and an SRE required a
greater duration of hospital stays and a greater duration of
hospital stays due to re-admission, than did patients with
bone metastases without SREs [10]. Similarly, patients
with bone metastases and SREs had a greater number of
hospital readmissions than patients with a primary cancer
diagnosis but no metastatic bone disease, suggesting that as
the disease progresses, there is a greater HRU burden [10].
In Portugal, a limited retrospective chart review of patients
with breast cancer (n = 121) or prostate cancer (n = 31)
and at least one SRE occurring within 12 months reported
high costs associated with SREs; these costs were pre-
dominantly due to hospitalization and medication [8]. In
the USA, a prospective study of 238 patients reported
substantial HRU associated with SREs, with considerable
numbers and durations of inpatient stays, numbers of out-
patient visits, and numbers of procedures [9]. The same
was concluded from the European cohort of the same study
(conducted in Germany, Italy, Spain, and the UK;
n = 631) in which all SREs were associated with consid-
erable HRU burden and costs [14, 15].
The availability of country-specific HRU data would
help to describe the burden of SREs on individual Euro-
pean healthcare systems and might help when assessing the
overall value of new treatment options. These data are of
particular relevance given the resource constraints under
which many healthcare systems now operate, as they would
allow an accurate estimation of resources required to
manage patients with SREs and could be used to determine
SRE-associated costs for use in budgeting. Thus, this study
was conducted to provide country-specific estimates of
HRU associated with SREs in eight European countries,
where robust data were previously unavailable.
Methods
Study design
This was a multinational, before-and-after, retrospective
study that enrolled patients from hospitals in Austria, the
Czech Republic, Finland, Greece, Poland, Portugal, Swe-
den, and Switzerland.
Patients
Eligible patients were aged 20 years or older, had bone
metastases secondary to breast, lung or prostate cancer or
bone lesions due to multiple myeloma, and had at least one
index SRE (an SRE preceded by an SRE-free period of at
least 6.5 months) within the 5-year time period between
July 1, 2004 and July 1, 2009. Patients were excluded from
the study if they were participating or had previously
participated in a denosumab clinical trial, died less than
2 weeks after the index SRE, or had chart data that were of
insufficient quality.
SRE data collection
SREs were defined as radiation to bone, pathologic fracture
(of long or other bone), surgery to bone or spinal cord
compression. To ensure a representative distribution of
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SREs in each country, a target maximum number of each
type of index SRE was assigned. Per country, this target
was 150 patients to reach the required 150 index SREs (one
index SRE per patient) as follows: radiation therapy to
bone (n = 60); long-bone pathologic fracture (n = 30);
other bone pathologic fracture (n = 30); surgery to bone
(n = 20); and spinal cord compression (n = 10). For all
SREs, data were extracted from patients’ hospital charts
beginning 3.5 months before the index SRE until 3 months
after the index SRE (Fig. 1a). Recruitment ceased when the
pre-specified target was reached for each type of index
SRE. Once a patient was enrolled into the study, data were
captured for all SREs occurring during the period after the
index SRE. For patients who experienced multiple SREs,
the data extraction period was extended to 3 months after
the last SRE that the patient experienced during the study
period (Fig. 1b). There was no limit to the number of SREs
included in the period after the index SRE, as long as the
SRE occurred within the 5-year inclusion period. In addi-
tion, patients’ baseline clinical and demographic charac-
teristics were captured.
Data collection and attribution of HRU
For single SREs, HRU was objectively attributed according
to study design: a period of 3 months, starting 3.5 months
before the index SRE, was used to establish baseline HRU
and the 14 day (0.5 month) period immediately before the
index SRE was used to estimate diagnostic HRU. To ensure
that there was no carry-over of HRU from any SREs that
occurred before the 3.5 month pre-index-SRE period, a pre-
ceding SRE-free period of a further 3 months was required
(Fig. 1a). Adjustments were made to account for differences
in the lengths of baseline and post-baseline periods. If mul-
tiple SREs were present at the same anatomical site and
within 21 days of the index SRE, all HRU was attributed to
the index SRE (Fig. 1b). If multiple SREs were observed at
the same anatomical site but outside the 21-day window, or at
different anatomical sites on the same or different days, the
study steering committee, comprising four clinicians and two
health economists (authors of this paper), attributed HRU to
the appropriate SRE based on their experience and opinion.
The steering committee was required to attribute HRU to an
SRE in only approximately 5 % of cases.
Primary HRU outcome measures recorded were: num-
ber and duration of inpatient hospital stays (overall and by
hospital unit type); number of procedures (overall and by
provider type); number of emergency room visits; number
of outpatient visits; and number of day-care hospital visits.
Outpatient visits and procedures were reviewed by an
expert panel to separate SRE-associated HRU from HRU















To ensure any HRU used to diagnose the SRE is included in the HRU burden for 
the SRE there is a two-week diagnosis period immediately prior to the SREc
Estimate of HRU associated with SRE = (post-SRE period + diagnosis period) – baseline periodd
• Multiple SREs observed at the same anatomical site and within a 21-day window
 – All HRU was attributed to the index SRE
• Multiple SREs observed at the same anatomical site but outside a 21-day window
 – Expert panel attributed HRU to the respective SRE
• Multiple SREs at different anatomical sites on the same or different days
 – Expert panel attributed HRU to the respective SRE
Index SRE  SRE  SRE
Bone
metastases
HRU, health resource utilisation; SRE, skeletal-related events. aTo ensure lack of carry-over of HRU from a 
previous SRE that occurred before the 3.5 month pre-SRE period, a clean window of an additional 3 months 
without an SRE was required. bFor multiple SREs, the post-index SRE observational period was extended to 
3 months following the last observed SRE. cAdded to the post-SRE period for the analysis. dAdjusted to 
allow for the different lengths of the periods.
Fig. 1 Study design and data
collection for patients with one
SRE (a), and multiple SREs (b)
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Statistical analysis
Statistical analyses were descriptive in nature and summa-
rized numbers of patients along with mean, median, standard
deviation (SD), quartile, minimum and maximum values.
Patient characteristics and HRU outcome measures were
summarized overall and by index SRE and subsequent SRE
type. Data are presented as mean (SD), unless stated
otherwise, because this describes the total resources used at
a population level better than the other values, and resource
use at this level is key to making healthcare policy decisions.
After adjustment for differences in the lengths of the
baseline and post-baseline periods, the change from base-
line was used to estimate HRU associated with each SRE.
Results
Study population
A total of 1022 patients were included from the eight
countries. Baseline demographics and clinical characteris-
tics are presented for the overall population and by country
(Table 1).
The proportion of female patients was notably lower in
Sweden (24.4 %) and higher in Switzerland (64.9 %) and
Austria (62.6 %) compared with the overall proportion
across all countries (45.7 %). Similarly, differences were
seen in the proportions of patients with each primary tumor
type across the countries: fewer enrolled patients had breast
cancer in Sweden (5.0 %) than in Austria (52.7 %) or the
Czech Republic (53.1 %); fewer enrolled patients in
Sweden (3.4 %) and the Czech Republic (5.4 %) had lung
cancer than in the other countries; and a smaller proportion
of patients in Austria (4.6 %) and Greece (9.9 %) had
prostate cancer than in Sweden (49.6 %).
In general, the majority of SREs recorded were single
events, with the exception of Finland where single SREs
accounted for 35.0 % of SREs. There was some variation
between countries in the mean time since diagnosis of bone
metastases, ranging from 4.7 months in Poland to
18.8 month in Switzerland).
Changes in the number and duration of inpatient
stays
Overall, an additional mean 0.5 (SD 1.2) inpatient stay was
required per radiation to bone event compared with base-
line. The corresponding increases for other SRE events
were: 1.2 (1.2) for long-bone pathologic fractures; 0.8 (1.2)
for other bone pathologic fractures; 1.5 (1.2) for surgery to
bone events; and 1.3 (1.5) for spinal cord compressions
(Fig. 2a).
The total duration of inpatient stays per SRE also
increased compared with baseline, by: 7.8 (14.8) days for
radiation to bone events; 20.9 (22.1) days for long-bone
pathologic fractures, 12.3 (19.5) days for other bone patho-
logic fractures; 18.8 (17.5) days for surgery to bone events;
and 22.2 (24.3) days for spinal cord compressions (Fig. 2b).
Country-specific changes in the number
and duration of inpatient stays
Changes from baseline in the number (Fig. 2a) and dura-
tion (Fig. 2b) of inpatient stays were generally similar
across countries, with a requirement for an additional 0.5–2
stays per SRE (Fig. 2a). In Finland, Sweden, and
Switzerland, long-bone pathologic fractures were associ-
ated with the greatest increase in number of inpatient stays,
with mean (SD) increases of 1.8 (1.8), 1.4 (0.9), and 1.8
(0.7) stays per event, respectively. In Austria, Finland, and
Greece, surgery to bone events were associated with the
greatest increase in number of inpatient stays per event
[mean (SD) increases of 2.0 (1.5), 2.1 (1.3) and 1.2 (1.1)
stays, respectively]. For the Czech Republic and Poland,
the SRE associated with the greatest increase in number of
inpatient stays was spinal cord compression, with mean
(SD) increases of 2.0 (2.0) and 2.1 (1.7) stays per event,
respectively. In general, SREs treated in Greece and Por-
tugal required fewer additional inpatient stays compared
with the other countries studied.
Greater variation was observed in the increase from
baseline in duration of inpatient stays compared with that
seen in the number of inpatient stays (Fig. 2), ranging from
approximately 6 to 37 days per SRE (Fig. 2b). The
increase in duration of inpatient stays per event was gen-
erally smaller for radiation to bone events than for other
SREs, and was similar across countries. In Finland, Poland
and Portugal, the greatest increase in duration of inpatient
stays per SRE was for long-bone pathologic fractures:
mean (SD) increases of 29.4 (34.6), 18.5 (16.1), and 32.1
(19.8) days, respectively. In Sweden, surgery to bone
resulted in the greatest mean (SD) increase in duration of
inpatient stays, at 28.5 (26.5) additional days per event. In
Austria, the Czech Republic, Greece and Switzerland, the
increase in duration of inpatient stays was greatest for
spinal cord compression, with mean (SD) increases of 31.4
(23.4), 23.1 (24.8), 11.1 (9.3), and 36.8 (35.0) days per
event, respectively.
Changes in the number of inpatient stays by hospital
unit type
Increases from baseline in the number of inpatient stays per
SRE most commonly involved [mean (SD) increase in
number of stays]: oncology units [0.2 (0.7)] and radiation
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Mean age, years 63.8 61.2 64.3 66.4 61.8 61.9 63.2 67.9 64.3
Female, n (%) 467 (45.7) 82 (62.6) 71 (54.6) 43 (36.8) 47 (38.8) 80 (53.3) 55 (43.7) 29 (24.4) 60 (64.9)
Geriatric age group, n (%)
\65 years 522 (51.1) 79 (60.3) 61 (46.9) 49 (41.9) 64 (52.9) 90 (60.0) 67 (53.2) 46 (38.7) 66 (51.6)
C65 years 500 (48.9) 52 (39.7) 69 (53.1) 68 (58.1) 57 (47.1) 60 (40.0) 59 (46.8) 73 (61.3) 62 (48.4)
C75 years 179 (17.5) 17 (13.0) 20 (15.4) 22 (18.8) 13 (10.7) 20 (13.3) 22 (17.5) 40 (33.6) 25 (19.5)
Radiation therapy,
n (%)
482 (47.2) 57 (43.5) 59 (45.4) 60 (51.3) 59 (48.8) 67 (44.7) 59 (46.8) 62 (52.1) 59 (46.1)
Pathologic fracture
(long bone), n (%)




241 (23.6) 22 (16.8) 33 (25.4) 30 (25.6) 32 (26.4) 30 (20.0) 29 (23.0) 27 (22.7) 38 (29.7)
Surgery to bone,
n (%)




82 (8.0) 10 (7.6) 10 (7.7) 10 (8.5) 10 (8.3) 9 (6.0) 12 (9.5) 10 (8.4) 11 (8.6)
ECOG statusa n (%)
0 107 (13.8) 31 (43.1) 10 (8.7) 4 (4.3) 14 (13.6) 6 (4.1) 4 (5.8) 8 (13.1) 30 (26.3)
1 318 (41.1) 31 (43.1) 58 (50.4) 35 (37.2) 38 (36.9) 56 (38.4) 32 (46.4) 18 (29.5) 50 (43.9)
2 234 (30.2) 7 (9.7) 34 (29.6) 36 (38.2) 41 (39.8) 56 (38.4) 16 (23.2) 20 (32.8) 24 (21.1)
3 103 (13.3) 3 (4.2) 10 (8.7) 19 (20.2) 9 (8.7) 25 (17.1) 14 (20.3) 13 (21.3) 10 (8.8)
4 12 (1.6) 0 (0.0) 3 (2.6) 0 (0.0) 1 (1.0) 3 (2.1) 3 (4.3) 2 (3.3) 0 (0.0)
Unknown 248 (–) 59 (–) 15 (–) 23 (–) 18 (–) 4 (–) 57 (–) 58 (–) 14 (–)
Primary tumor diagnosis, n (%)
Breast cancer 321 (31.4) 69 (52.7) 69 (53.1) 26 (22.2) 19 (15.7) 50 (33.3) 41 (32.5) 6 (5.0) 41 (32.0)
Lung cancer 184 (18.0) 25 (19.1) 7 (5.4) 19 (16.2) 41 (33.9) 31 (20.7) 41 (32.5) 4 (3.4) 16 (12.5)
Prostate cancer 267 (26.1) 6 (4.6) 46 (35.4) 49 (41.9) 12 (9.9) 28 (18.7) 31 (24.6) 59 (49.6) 36 (28.1)
Multiple myeloma 250 (24.5) 31 (23.7) 8 (6.2) 23 (19.7) 49 (40.5) 41 (27.3) 13 (10.3) 50 (42.0) 35 (27.3)
SRE status, n (%)
Single 597 (58.4) 73 (55.7) 93 (71.5) 41 (35.0) 85 (70.2) 97 (64.7) 70 (55.6) 60 (50.4) 78 (60.9)
Multiple 425 (41.6) 58 (44.3) 37 (28.5) 76 (65.0) 36 (29.8) 53 (35.3) 56 (44.4) 59 (49.6) 50 (39.1)
Time since bone metastases, months
n 754 88 120 94 71 109 111 69 92
Mean 11.14 8.30 13.48 16.72 6.01 4.67 6.24 16.37 18.76
Median 1.82 1.45 3.79 3.14 1.12 1.02 1.18 7.98 6.74
Bone metastases sitesa, n (%)
1–2 634 (82.1) 91 (91.0) 91 (74.6) 57 (60.6) 67 (93.1) 102
(93.6)
113 (100) 48 (69.6) 65 (69.9)
3–4 66 (8.5) 6 (6.0) 19 (15.6) 15 (16.0) 3 (4.2) 3 (2.8) 0 (0.0) 12 (17.4) 8 (8.6)
C5 72 (9.3) 3 (3.0) 12 (9.8) 22 (23.4) 2 (2.8) 4 (3.7) 0 (0.0) 9 (13.0) 20 (21.5)
Missing 250 (–) 31 (–) 8 (–) 23 (–) 49 (–) 41 (–) 13 (–) 50 (–) 35 (–)
Bisphosphonate use, n (%)
Baseline 330 (40.2) 36 (27.5) 62 (47.7) 47 (40.2) 23 (19.0) 49 (32.7) 30 (23.8) 35 (29.4) 48 (37.5)
Post-SRE 644 (63.0) 84 (64.1) 101 (77.7) 80 (68.4) 64 (52.9) 95 (63.3) 76 (60.3) 53 (44.5) 91 (71.1)
ECOG Eastern Cooperative Oncology Group
a Percentages calculated for the number of subjects with available data
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units [0.1 (0.4)] for radiation to bone events; orthopedic
units [0.5 (0.6)] for long-bone pathologic fractures; internal
medicine units [0.2 (0.6)] and oncology units [0.2 (0.7)] for
other bone pathologic fractures; orthopedic units [0.6 (0.6)]
for surgery to bone events and oncology units [0.3 (0.9)]
for spinal cord compression.
Country-specific treatment practices were evident: in
Austria, Finland and Greece, SREs were predominantly
managed in orthopedic and oncology units, whereas in
Sweden and Portugal a variety of specialist units were
used, including urology and pneumology. In contrast to the
other countries studied, in Switzerland the majority of
SREs were managed in internal medicine units.
Overall change in the number of procedures
Overall, all SREs required an increased number of proce-
dures from baseline (Fig. 3). For radiation to bone events
an additional mean (SD) of 8.5 (7.5) procedures were
required per event. Long-bone pathologic fractures
required an additional mean 6.1 (SD 7.1) procedures per
event; this was similar for other bone pathologic fractures
at 5.9 (6.6) additional procedures per event. Surgery to
bone events required an additional mean 6.4 (SD 7.9)
procedures and spinal cord compressions required 9.6 (8.2)
additional procedures per event (Fig. 3). Increases in the
frequency of procedures from baseline were generally of
similar magnitude across all countries, ranging from
approximately 2 to 14 procedures per SRE, although the
increase was lower in Poland and Sweden than in the other
countries (Fig. 3).
Changes in emergency room visits
Overall, increases from baseline in the frequency of
emergency room visits were relatively small, with an
additional mean (SD) of 0.1 (0.7) visits per SRE for radi-
ation to bone, 0.3 (0.7) for long-bone pathologic fractures,
0.2 (0.9) for other bone pathologic fractures, 0.2 (0.8) for
surgery to bone and 0.5 (0.8) for spinal cord compressions.
The greatest increases number of in emergency room visits
per SRE were noted in Finland and Portugal, particularly
associated with spinal cord compressions: mean (SD) of
1.2 (0.8) visits (Finland) and 1.1 (1.3) visits (Portugal).
Changes in outpatient and day care visits
Collectively, outpatient visits increased in frequency from
baseline by a mean (SD) of 4.2 (6.6) visits per SRE for
radiation to bone events, 2.6 (4.7) for long-bone pathologic
fractures, 4.0 (5.8) for other bone pathologic fractures, 2.7
(5.5) for surgery to bone events and 4.1 (6.4) for spinal
cord compressions (Fig. 4a). Across countries, the increase
from baseline in outpatient visits ranged from approxi-
mately 1 to 8 visits per SRE and was generally highest in
Finland.
Day care visits also increased in overall frequency from
























































Radiation to bone PF - long bone PF - other bone Surgery to bone Spinal cord compression
(a)
(b)
Fig. 2 Mean (SD) change from
baseline for number (a), and
total duration (b) inpatient
stays. PF pathologic fracture
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to bone, 0.8 (2.7) for long-bone pathologic fractures, 1.4
(3.6) for other bone pathologic fractures, 1.7 (2.8) for
surgery to bone events, and 2.0 (4.8) for spinal cord
compressions (Fig. 4b). Across countries, day-care visits
increased most notably in Portugal and Austria, with sub-
stantial increases also recorded in Sweden and Greece,
particularly for spinal cord compression. Values of zero
were recorded for Switzerland as these data were not
available to investigators.
Discussion
This study is the first multinational, European, before-and-
after, retrospective study to describe SRE-associated HRU
in real-world practice across a number of tumor types. All
SREs were associated with substantial HRU, demonstrated
by increases from baseline in the number and duration of
inpatient stays, as well as in the number of procedures and
outpatient, emergency room, and day-care visits. The pri-
mary strength of this study is that the HRU data captured
here are representative of clinical practice across eight
European countries.
In all countries, all SRE types were associated with
increases from baseline in the number and duration of
inpatient stays; however, these increases differed according
to SRE type. For example, surgery to bone and spinal cord
compression contributed up to three times more HRU than
radiation to bone. Increases in inpatient HRU for patho-
logic fractures of long bones were similar to those for
surgery to bone or spinal cord compression, and were
greater than increases in HRU for fractures affecting other
bones, perhaps because longer periods of immobility or
more extensive medical interventions were required than
for more minor fractures. Our data are consistent with those
from other European studies that report substantial inpa-
tient HRU as a result of surgery to bone, spinal cord
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Fig. 4 Mean (SD) change from
baseline for number of
outpatient visits (a) and number
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Fig. 3 Mean (SD) change from
baseline for number of
procedures. PF pathologic
fracture
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study is the first to distinguish between pathologic fractures
of long bones and those of other bones in terms of HRU in
clinical practice.
Some variations in the pattern of HRU were observed in
different countries, one example being the duration of
inpatient stays: Greece and Poland generally had the
smallest increases from baseline in duration of inpatient
stays, and Switzerland had the largest increases. While
small increases in the duration of inpatient stays across
most SRE types were seen in Portugal, long-bone patho-
logic fracture was associated with one of the largest
increases in mean duration of inpatient stays of all the
countries. This may indicate a difference in the approach to
care for this fracture type compared with other SREs in
Portugal.
The majority of inter-country differences in HRU were
observed in the change from baseline in the numbers of
outpatient visits, day-care visits and procedures. For
example, in Finland and Portugal, long-bone pathologic
fracture accounted for the largest increase from baseline in
outpatient HRU of all SREs, whereas in most other coun-
tries, this SRE type was associated with small increases in
outpatient HRU. This suggests that there are differences in
treatment practice, such as the use of less invasive surgical
procedures that may account for the increased use of out-
patient or day-care facilities in some countries. The
increase in the use of outpatient or day-care clinics may
also reflect the accessibility of such facilities in certain
countries. If patients are required to travel long distances
for treatment, this may make overnight stays necessary,
thus increasing inpatient stays and concurrently decreasing
outpatient visits. In Switzerland, Austria, and the Czech
Republic, the largest increases in outpatient visits and
number of procedures were for spinal cord compression,
but in Greece, radiation to bone accounted for the largest
changes. The increases in number of procedures and out-
patient and day-care visits associated with radiation to bone
in many countries is perhaps unsurprising, as radiotherapy
is recommended by guidelines for the treatment of pain
associated with metastatic bone disease [16, 17], a symp-
tom experienced by up to 90 % of patients in the later
stages of metastatic cancer [16]. A large review of
worldwide radiation practice patterns found that multiple
fractions of radiation therapy were preferred to single
fractions to treat pain associated with bone metastases in
Europe [18]. Both multiple-fraction and single-fraction
treatment regimens have been shown to be equally effec-
tive in palliating pain [19]; therefore, encouraging the use
of single-fraction therapy may help to reduce outpatient-
and procedure-related HRU.
The HRU associated with SREs reported here, and the
subsequent implications for costs [11, 12, 20, 21], highlight
the potential reduction in HRU that could be achieved
using BTAs to prevent SREs. Indeed, European guidelines
recommend BTAs, such as bisphosphonates and deno-
sumab, for patients with bone metastases secondary to
advanced malignancies [17, 22–26]. In patients with breast
cancer, ibandronate significantly decreased the incidence of
new bone events by 38 % and delayed the time to first SRE
compared with placebo (50.6 vs. 33.1 weeks, respectively)
[27]. Similar delays in the time to first SRE were observed
in patients with breast cancer receiving pamidronate
compared with those receiving placebo [28]. In patients
with prostate cancer, zoledronic acid significantly delayed
the time to first SRE, and reduced the ongoing risk of SREs
by 36 %, compared with placebo [29]. A recent study
reported that ibandronate was inferior to zoledronic acid
for reducing the frequency of SREs in patients with breast
cancer [30], and another study reported that zoledronic acid
significantly decreased the risk of developing an SRE by an
additional 20 % compared with pamidronate [31]. In
addition, denosumab was shown to be superior to zole-
dronic acid in delaying or preventing SREs in patients with
advanced solid tumors [32–36].
Despite the potential benefits of treatment and contrary
to guidelines and published evidence, our study found that
only 40 % of patients were receiving bisphosphonates at
baseline. After experiencing an SRE, 37 % of patients
remained untreated and studies suggest that these patients
were at risk of further SREs [29, 37] and subsequent
resource use. Our data reflect the findings of a large
European patient chart audit in which only 53 % of patients
with bone metastases received BTA treatment. Further-
more, the audit indicated that 17 % were expected never to
receive treatment, reflecting a possible gap in patient care
[38].
The patient populations in this study differed from those
in clinical trials. Indeed, in clinical trials of BTAs in
patients with bone metastases secondary to cancer,
asymptomatic SREs are often captured by regular exami-
nations, including as bone scanning, used during follow-up
[32, 33, 39]. Recent clinical trials have used an alternative
set of endpoints, referred to as symptomatic skeletal-related
events (SSEs), comprising radiation to bone, symptomatic
pathologic fracture, surgery to bone and symptomatic
spinal cord compression [1, 40]. It is likely that all SSEs
were captured in the present study, but that some asymp-
tomatic SREs may not have been identified owing to the
absence of regular scans.
The main limitation of this study is the probable
underestimation of SRE-associated HRU. In this study,
most patients had one or two sites of bone metastasis;
therefore, the HRU for individuals with multiple bone
metastases was probably not fully captured because these
patients may require more HRU than those with fewer sites
of metastasis. In addition, HRU outside the hospital setting,
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such as that associated with home visits, is difficult to
assess and was not captured in this study. Home visits have
been shown to be particularly important in the management
of pathologic fractures [9], and may also become important
for other SREs, such as spinal cord compression, owing to
the loss of mobility and independence that occurs as
metastatic bone disease progresses. Furthermore, patients
with more advanced disease may be treated in a hospice
facility, and hospice HRU may not have been fully cap-
tured in our study.
Another limitation of this study is that the distribution of
SREs may not accurately reflect that of a real-world setting,
owing to recruitment according to predefined targets (in
some instances target numbers of patients were not met). In
addition, at the Finnish centre, selection bias was observed
for radiation to bone. Patients receiving this treatment were
enrolled only from palliative wards, where associated HRU
may have been higher owing to the level of care delivered at
this type of facility. The other HRU data from Finland are,
however, considered representative. Despite the limitations,
this study provides valuable information on the HRU asso-
ciated with SREs in clinical practice.
In conclusion, this study demonstrates that in real-world
practice, SREs are associated with substantial increases in
HRU across all countries investigated. Previous estimates
of the contributions of pathologic fractures to HRU may
have been imprecise, owing to grouping of all fractures
together in other studies. The availability of more effective
and better tolerated BTAs to prevent SREs may help to
reduce the burden placed on healthcare resources. Further
studies on the effect of delaying SREs on HRU and costs in
real-world practice are warranted.
Acknowledgments This study was sponsored by Amgen. We thank
all of the investigators, coordinators, and other staff who participated
in this study. Review of data from Finland was provided by Professor
Carl Blomqvist. We are also grateful to Laurence Carpenter who was
the study programmer. Medical writing support was provided by Leon
Adams from Watermeadow Medical funded by Amgen (Europe)
GmbH. Editorial support was provided by Emma Thomas of Amgen
(Europe) GmbH. Additional statistical review was provided by Susan
Shepherd of Amgen Ltd.
Open Access This article is distributed under the terms of the
Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Parker, C., Nilsson, S., Heinrich, D., Helle, S.I., O’Sullivan, J.M.,
Fossa, S.D., Chodacki, A., Wiechno, P., Logue, J., Seke, M.,
Widmark, A., Johannessen, D.C., Hoskin, P., Bottomley, D.,
James, N.D., Solberg, A., Syndikus, I., Kliment, J., Wedel, S.,
Boehmer, S., Dall’Oglio, M., Franzen, L., Coleman, R., Vogel-
zang, N.J., O’Bryan-Tear, C.G., Staudacher, K., Garcia-Vargas,
J., Shan, M., Bruland, O.S., Sartor, O., Investigators, A.: Alpha
emitter radium-223 and survival in metastatic prostate cancer.
N. Engl. J. Med. 369(3), 213–223 (2013). doi:10.1056/
NEJMoa1213755
2. Coleman, R.E.: Clinical features of metastatic bone disease and
risk of skeletal morbidity. Clin. Cancer Res. 12(20 Pt 2), 6243s–
6249s (2006). doi:10.1158/1078-0432.CCR-06-0931
3. Coleman, R.E.: Skeletal complications of malignancy. Cancer
80(8 Suppl), 1588–1594 (1997). doi:10.1002/(SICI)1097-
0142(19971015)80
4. Costa, L., Badia, X., Chow, E., Lipton, A., Wardley, A.: Impact
of skeletal complications on patients’ quality of life, mobility,
and functional independence. Support. Care Cancer 16(8),
879–889 (2008). doi:10.1007/s00520-008-0418-0
5. Norgaard, M., Jensen, A.O., Jacobsen, J.B., Cetin, K., Fryzek,
J.P., Sorensen, H.T.: Skeletal related events, bone metastasis and
survival of prostate cancer: a population based cohort study in
Denmark (1999 to 2007). J. Urol. 184(1), 162–167 (2010).
doi:10.1016/j.juro.2010.03.034
6. Saad, F., Lipton, A., Cook, R., Chen, Y.M., Smith, M., Coleman,
R.: Pathologic fractures correlate with reduced survival in
patients with malignant bone disease. Cancer 110(8), 1860–1867
(2007). doi:10.1002/cncr.22991
7. Sathiakumar, N., Delzell, E., Morrisey, M.A., Falkson, C., Yong,
M., Chia, V., Blackburn, J., Arora, T., Brill, I., Kilgore, M.L.:
Mortality following bone metastasis and skeletal-related events
among women with breast cancer: a population-based analysis of
U.S. Medicare beneficiaries, 1999-2006. Breast Cancer Res.
Treat. 131(1), 231–238 (2012). doi:10.1007/s10549-011-1721-x
8. Felix, J., Andreozzi, V., Soares, M., Borrego, P., Gervasio, H.,
Moreira, A., Costa, L., Marcelo, F., Peralta, F., Furtado, I., Pina,
F., Albuquerque, C., Santos, A., Passos-Coelho, J.L.: Hospital
resource utilization and treatment cost of skeletal-related events
in patients with metastatic breast or prostate cancer: estimation
for the Portuguese National Health System. Value Health. 14(4),
499–505 (2011). doi:10.1016/j.jval.2010.11.014
9. Mahmood, A., Ghazal, H., Fink, M.G., Patel, M., Atchison, C.,
Wei, R., Suenaert, P., Pinzone, J.J., Slasor, P., Chung, K.: Health-
resource utilization attributable to skeletal-related events in
patients with advanced cancers associated with bone metastases:
results of the US cohort from a multicenter observational study.
Comm. Oncol. 9, 148–157 (2012)
10. Pockett, R.D., Castellano, D., McEwan, P., Oglesby, A., Barber,
B.L., Chung, K.: The hospital burden of disease associated with
bone metastases and skeletal-related events in patients with breast
cancer, lung cancer, or prostate cancer in Spain. Eur. J. Cancer
Care (Engl.) 19(6), 755–760 (2010). doi:10.1111/j.1365-2354.
2009.01135.x
11. Groot, M.T., Boeken Kruger, C.G., Pelger, R.C., Uyl-de Groot,
C.A.: Costs of prostate cancer, metastatic to the bone, in the
Netherlands. Eur. Urol. 43(3), 226–232 (2003). doi:10.1016/
S0302-2838(03)00007-1
12. Botteman, M., Barghout, V., Stephens, J., Hay, J., Brandman, J.,
Aapro, M.: Cost effectiveness of bisphosphonates in the man-
agement of breast cancer patients with bone metastases. Ann.
Oncol. 17(7), 1072–1082 (2006). doi:10.1093/annonc/mdl093
13. Delea, T., McKiernan, J., Brandman, J., Edelsberg, J., Sung, J.,
Raut, M., Oster, G.: Retrospective study of the effect of skeletal
complications on total medical care costs in patients with bone
metastases of breast cancer seen in typical clinical practice.
J. Support. Oncol. 4(7), 341–347 (2006)
14. Hechmati, G., Cure, S., Gouepo, A., Hoefeler, H., Lorusso, V.,
Luftner, D., Duran, I., Garzon-Rodriguez, C., Ashcroft, J., Wei,
Health resource utilization associated with skeletal-related events: results from a… 719
123
R., Ghelani, P., Bahl, A.: Cost of skeletal-related events in
European patients with solid tumours and bone metastases: data
from a prospective multinational observational study. J. Med.
Econ. 16(5), 69–700 (2013). doi:10.3111/13696998.2013.779921
15. Hoefeler, H., Duran, I., Hechmati, G., Garzon Rodriguez, C.,
Lu¨ftner, D., Ashcroft, J., Bahl, A., Atchison, C., Wei, R., Tho-
mas, E., Lorusso, V.: Health resource utilization associated with
skeletal-related events in patients with bone metastases: Results
from a multinational retrospective––prospective observational
study––a cohort from 4 European countries. J. Bone Oncol. 3(2),
40–48 (2014)
16. Bodei, L., Lam, M., Chiesa, C., Flux, G., Brans, B., Chiti, A.,
Giammarile, F.: EANM procedure guideline for treatment of
refractory metastatic bone pain. Eur. J. Nucl. Med. Mol. Imaging
35(10), 1934–1940 (2008). doi:10.1007/s00259-008-0841-y
17. Coleman, R., Body, J.J., Aapro, M., Hadji, P., Herrstedt, J., on
behalf of the, E.G.W.G: Bone health in cancer patients: ESMO
Clinical Practice Guidelines. Ann. Oncol. (2014). doi:10.1093/
annonc/mdu103
18. Bradley, N.M., Husted, J., Sey, M.S., Husain, A.F., Sinclair, E.,
Harris, K., Chow, E.: Review of patterns of practice and patients’
preferences in the treatment of bone metastases with palliative
radiotherapy. Support. Care Cancer 15(4), 373–385 (2007).
doi:10.1007/s00520-006-0161-3
19. Sze, W.M., Shelley, M., Held, I., Mason, M.: Palliation of
metastatic bone pain: single fraction versus multifraction radio-
therapy—a systematic review of the randomised trials. Cochrane
Database Syst. Rev.(2), Cd004721 (2004). doi:10.1002/
14651858.cd004721
20. Hillner, B.E., Weeks, J.C., Desch, C.E., Smith, T.J.: Pamidronate
in prevention of bone complications in metastatic breast cancer: a
cost-effectiveness analysis. J. Clin. Oncol. 18(1), 72–79 (2000)
21. Lage, M.J., Barber, B.L., Harrison, D.J., Jun, S.: The cost of
treating skeletal-related events in patients with prostate cancer.
Am. J. Manag. Care 14(5), 317–322 (2008)
22. Cardoso, F., Harbeck, N., Fallowfield, L., Kyriakides, S., Senkus,
E., Group E.G.W: Locally recurrent or metastatic breast cancer:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann. Oncol. 23(Suppl 7), vii11–vii19 (2012). doi:10.
1093/annonc/mds232
23. Escudier, B., Eisen, T., Porta, C., Patard, J.J., Khoo, V., Algaba,
F., Mulders, P., Kataja, V., Group E.G.W: Renal cell carcinoma:
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann. Oncol. 23(Suppl 7), vii65–vii71 (2012). doi:10.
1093/annonc/mds227
24. Horwich, A., Parker, C., de Reijke, T., Kataja, V., Group E.G.W:
Prostate cancer: ESMO Clinical Practice Guidelines for diagno-
sis, treatment and follow-up. Ann. Oncol. 24(Suppl 6), vi106–
vi114 (2013). doi:10.1093/annonc/mdt208
25. Mottet, N., Bastian, P.J., Bellmunt, J., van den Bergh, R.C.N.,
Bolla, M., van Casteren, N.J., Cornford, P., Joniau, S., Mason,
M.D., Matveev, V., van der Kwast, T.H., van der Poel, H.,
Rouvie`re, O., Wiegel, T.: EAU Clinical guidelines: Guidelines on
Prostate Cancer. (2014). Accessed 27 May 2014
26. Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E.,
Group E.G.W: Metastatic non-small-cell lung cancer (NSCLC):
ESMO Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann. Oncol. 23(Suppl 7), vii56–vii64 (2012). doi:10.
1093/annonc/mds226
27. Body, J.J., Diel, I.J., Lichinitser, M.R., Kreuser, E.D., Dornoff,
W., Gorbunova, V.A., Budde, M., Bergstrom, B.: Intravenous
ibandronate reduces the incidence of skeletal complications in
patients with breast cancer and bone metastases. Ann. Oncol.
14(9), 1399–1405 (2003)
28. Theriault, R.L., Lipton, A., Hortobagyi, G.N., Leff, R., Gluck, S.,
Stewart, J.F., Costello, S., Kennedy, I., Simeone, J., Seaman, J.J.,
Knight, R.D., Mellars, K., Heffernan, M., Reitsma, D.J.: Pami-
dronate reduces skeletal morbidity in women with advanced
breast cancer and lytic bone lesions: a randomized, placebo-
controlled trial. Protocol 18 Aredia Breast Cancer Study Group.
J. Clin. Oncol. 17(3), 846–854 (1999)
29. Saad, F., Gleason, D.M., Murray, R., Tchekmedyian, S., Venner,
P., Lacombe, L., Chin, J.L., Vinholes, J.J., Goas, J.A., Zheng, M.:
Long-term efficacy of zoledronic acid for the prevention of
skeletal complications in patients with metastatic hormone-re-
fractory prostate cancer. J. Natl Cancer Inst. 96(11), 879–882
(2004)
30. Barrett-Lee, P., Casbard, A., Abraham, J., Hood, K., Coleman, R.,
Simmonds, P., Timmins,H.,Wheatley,D.,Grieve, R., Griffiths,G.,
Murray, N.: Oral ibandronic acid versus intravenous zoledronic
acid in treatment of bone metastases from breast cancer: a ran-
domised, open label, non-inferiority phase 3 trial. Lancet Oncol.
15(1), 114–122 (2014). doi:10.1016/s1470-2045(13)70539-4
31. Gordon, D.H.: Efficacy and safety of intravenous bisphospho-
nates for patients with breast cancer metastatic to bone: a review
of randomized, double-blind, phase III trials. Clin. Breast Cancer
6(2), 125–131 (2005). doi:10.3816/CBC.2005.n.014
32. Fizazi, K., Carducci, M., Smith, M., Damiao, R., Brown, J., Karsh,
L., Milecki, P., Shore, N., Rader, M., Wang, H., Jiang, Q., Tadros,
S., Dansey, R., Goessl, C.: Denosumab versus zoledronic acid for
treatment of bone metastases in men with castration-resistant
prostate cancer: a randomised, double-blind study. Lancet
377(9768), 813–822 (2011). doi:10.1016/s0140-6736(10)62344-6
33. Henry, D., Vadhan-Raj, S., Hirsh, V., von Moos, R., Hungria, V.,
Costa, L., Woll, P.J., Scagliotti, G., Smith, G., Feng, A., Jun, S.,
Dansey, R., Yeh, H.: Delaying skeletal-related events in a ran-
domized phase 3 study of denosumab versus zoledronic acid in
patients with advanced cancer: an analysis of data from patients
with solid tumors. Support. Care Cancer 22(3), 679–687 (2014).
doi:10.1007/s00520-013-2022-1
34. Lipton, A., Fizazi, K., Stopeck, A.T., Henry, D.H., Brown, J.E.,
Yardley, D.A., Richardson, G.E., Siena, S., Maroto, P., Clemens,
M., Bilynskyy, B., Charu, V., Beuzeboc, P., Rader, M., Viniegra,
M., Saad, F., Ke, C., Braun, A., Jun, S.: Superiority of denosumab
to zoledronic acid for prevention of skeletal-related events: a
combined analysis of 3 pivotal, randomised, phase 3 trials. Eur.
J. Cancer 48(16), 3082–3092 (2012). doi:10.1016/j.ejca.2012.08.
002
35. Smith, M.R., Saad, F., Coleman, R., Shore, N., Fizazi, K.,
Tombal, B., Miller, K., Sieber, P., Karsh, L., Damiao, R., Tam-
mela, T.L., Egerdie, B., Van Poppel, H., Chin, J., Morote, J.,
Gomez-Veiga, F., Borkowski, T., Ye, Z., Kupic, A., Dansey, R.,
Goessl, C.: Denosumab and bone-metastasis-free survival in men
with castration-resistant prostate cancer: results of a phase 3,
randomised, placebo-controlled trial. Lancet 379(9810), 39–46
(2012). doi:10.1016/s0140-6736(11)61226-9
36. Stopeck, A.T., Lipton, A., Body, J.J., Steger, G.G., Tonkin, K., de
Boer, R.H., Lichinitser, M., Fujiwara, Y., Yardley, D.A., Vinie-
gra, M., Fan, M., Jiang, Q., Dansey, R., Jun, S., Braun, A.:
Denosumab compared with zoledronic acid for the treatment of
bone metastases in patients with advanced breast cancer: a ran-
domized, double-blind study. J. Clin. Oncol. 28(35), 5132–5139
(2010). doi:10.1200/jco.2010.29.7101
37. Tchekmedyian, N.S., Chen, Y.M., Saad, F.: Disease progression
increases the risk of skeletal-related events in patients with bone
metastases from castration-resistant prostate cancer, lung cancer,
or other solid tumors. Cancer Invest. 28(8), 849–855 (2010).
doi:10.3109/07357907.2010.483508
38. Casas, A., Lebret, T., Cavo, M., Woll, P.J., Deleplace, C., Ken-
nedy, C., Jackisch, C.: Insights into the management of bone
metastases: a comprehensive European survey. Support. Care
Cancer 20(Suppl. 1), S88 (2012)
720 J.-J. Body et al.
123
39. Rosen, L.S., Gordon, D.H., Dugan Jr, W., Major, P., Eisenberg,
P.D., Provencher, L., Kaminski, M., Simeone, J., Seaman, J.,
Chen, B.L., Coleman, R.E.: Zoledronic acid is superior to
pamidronate for the treatment of bone metastases in breast car-
cinoma patients with at least one osteolytic lesion. Cancer 100(1),
36–43 (2004). doi:10.1002/cncr.11892
40. Smith, M.R., Coleman, R.E., Klotz, L., Pittman, K., Milecki, P.,
Ng, S., Chi, K.N., Balakumaran, A., Wei, R., Wang, H., Braun, A.,
Fizazi, K.: Denosumab for the prevention of skeletal complications
in metastatic castration-resistant prostate cancer: comparison of
skeletal-related events and symptomatic skeletal events. Ann.
Oncol. 26(2), 368–374 (2015). doi:10.1093/annonc/mdu519
Health resource utilization associated with skeletal-related events: results from a… 721
123
